Cite
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours
MLA
Aya El Helali, et al. A First-in-Human Phase I Dose-Escalation Trial of the Novel Therapeutic Peptide, ALM201, Demonstrates a Favourable Safety Profile in Unselected Patients with Ovarian Cancer and Other Advanced Solid Tumours. July 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....743ea9c16821a65b88f7554b9f484464&authtype=sso&custid=ns315887.
APA
Aya El Helali, Ruth Plummer, Gordon C. Jayson, Vicky M. Coyle, Yvette Drew, Nerissa Mescallado, Noor Harris, Andrew R. Clamp, Janine McCann, Helen Swaisland, Richard D. Kennedy, Aaron N. Cranston, & Richard H. Wilson. (2022). A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
Chicago
Aya El Helali, Ruth Plummer, Gordon C. Jayson, Vicky M. Coyle, Yvette Drew, Nerissa Mescallado, Noor Harris, et al. 2022. “A First-in-Human Phase I Dose-Escalation Trial of the Novel Therapeutic Peptide, ALM201, Demonstrates a Favourable Safety Profile in Unselected Patients with Ovarian Cancer and Other Advanced Solid Tumours,” July. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....743ea9c16821a65b88f7554b9f484464&authtype=sso&custid=ns315887.